Ovid Therapeutics Inc. has provided an update on its neurotherapeutics pipeline, highlighting several clinical-stage programs targeting conditions driven by neural hyperexcitability. The company is advancing OV329, a GABA-aminotransferase inhibitor, for drug-resistant adult focal onset seizures. Phase 1 results showed a strong safety profile, positive biomarker outcomes, and inhibitory effects comparable to or exceeding those of vigabatrin. The next phase for OV329 includes a Phase 2a trial, with topline results expected in mid-2027. Ovid is also developing oral formulations in its potassium-chloride cotransporter 2 (KCC2) direct activator portfolio. OV4071 is being prepared for indications such as psychosis associated with Parkinson's disease, Lewy body dementia, and schizophrenia, with regulatory submissions and a proof-of-mechanism study planned. Another candidate, OV4041, is targeting generalized anxiety disorder and Rett syndrome, with late-stage preclinical development underway. The company reports a cash runway expected to fund operations into the second half of 2028. You can access the full presentation through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ovid Therapeutics Inc. published the original content used to generate this news brief on December 18, 2025, and is solely responsible for the information contained therein.
Comments